Publications

Share
Print
Share
Print

Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation. N Engl J Med. 2020 Feb 27;382(9):822-834

ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity. Nature. 2020 Feb 19.

T cell–derived interferon-γ programs stem cell death in immune-mediated intestinal damageSci Immunol. 2019 Dec 6;4(42).

Cancer biology as revealed by the research autopsy. Nat Rev Cancer. 2019 Dec;19(12):686-697

Lactose drives Enterococcus expansion to promote graft-versus-host disease. Science. 2019 Nov 29;366(6469):1143-1149.

First-in-human imaging with 89Zr-Df-IAB22M2C anti-CD8 minibody in patients with solid malignancies: preliminary pharmacokinetics, biodistribution, and lesion targeting. J Nucl Med. 2019 Oct 4.

Glutamine independence is a selectable feature of pluripotent stem cells. Nat Metab. 2019 Jul;1(7):676-687

T Cell Recruitment to the Intestinal Stem Cell Compartment Drives Immune-Mediated Intestinal Damage after Allogeneic Transplantation. Immunity. 2019 Jul 16;51(1):90-103.

T cell receptor‐based cancer immunotherapy: Emerging efficacy and pathways of resistance. Immunol Rev. 2019 Jul;290(1):127-147

Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition. Blood Adv. 2019 Jul 9;3(13):2040-2044

T cell stemness and dysfunction in tumors are triggered by a common mechanism. Science. 2019 Mar 29;363(6434)

Rational design of anti-GITR-based combination immunotherapy. Nat Med. 2019 May;25(5):759-766

TOX is a critical regulator of tumour-specific T cell differentiation. Nature. 2019 Jul;571(7764):270-274.

In situ vaccination with defined factors overcomes T-cell exhaustion in distant tumors. J Clin Invest. 2019 Jul 22;129(8):3435-3447.

T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy. J Clin Invest. 2019 Feb 25;129(4):1551-1565

Transcriptomic Profiling of the Tumor Microenvironment Reveals Distinct Subgroups of Clear cell Renal Cell Cancer - Data from a Randomized Phase III Trial. Cancer Discov. 2019 Apr;9(4):510-525.

Pulsatile MEK inhibition improves anti-tumor immunity and T cell function in murine Kras mutant lung cancer Cell Rep. 2019 Apr 16;27(3):806-819

Cancer Metabolism Drives a Stromal Regenerative Response. Cell Metab. 2019 Mar 5;29(3):576-591

PD-L1 Expression in Urothelial Carcinoma With Predominant or Pure Variant Histology. Am J Surg Pathol. 2019 Jul;43(7):920-927

NK cell–mediated cytotoxicity contributes to tumor control by a cytostatic drug combination. Science. 2018 Dec 21;362(6421):1416-1422.

Gut microbiota injury in allogeneic haematopoietic stem cell transplantation Nat Rev Cancer. 2018 May;18(5):283-295.

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline J Clin Oncol. 2018 Jun 10;36(17):1714-1768

Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. J Clin Oncol. 2018 Mar 1;36(7):633-641.

Rejection of immunogenic tumor clones is limited by clonal fraction. Elife. 2018 Nov 30;7. pii: e41090.

Non-conventional Inhibitory CD4+Foxp3–PD-1hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity. Cancer Cell. 2018 Jun 11;33(6):1017-1032

Proteomic profiling of antibody-inducing immunogens in tumor tissue identifies PSMA1, LAP3, ANXA3, and maspin as colon cancer markers. Oncotarget. 2017 Dec 22;9(3):3996-4019.

Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity. Nat Med. 2017 Feb;23(2):242-249

Chromatin states define tumour-specific T cell dysfunction and reprogramming. Nature. 2017 May 25;545(7655):452-456

Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature. 2017 Nov 23;551(7681):512-516.

Inhibition of AKT-signaling uncouples cellular differentiation from expansion for receptor-engineered T cells. JCI Insight. 2017 Dec 7; 2(23)

Heterogeneous Tumor Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient Cell. 2017 Aug 24;170(5)

Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells. Nature. 2016 Nov 17;539(7629):443-447